Canntab Therapeutics Limited Stock Revenue
| CTABF Stock | USD 0.0001 0.00 0.00% |
Canntab Therapeutics Limited fundamentals help investors to digest information that contributes to Canntab Therapeutics' financial success or failures. It also enables traders to predict the movement of Canntab Pink Sheet. The fundamental analysis module provides a way to measure Canntab Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Canntab Therapeutics pink sheet.
Canntab |
Canntab Therapeutics Limited Company Revenue Analysis
Canntab Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Canntab Therapeutics Revenue | 293.36 K |
Most of Canntab Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Canntab Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Canntab Therapeutics Limited reported 293.36 K of revenue. This is 100.0% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Canntab Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Canntab Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Canntab Therapeutics could also be used in its relative valuation, which is a method of valuing Canntab Therapeutics by comparing valuation metrics of similar companies.Canntab Therapeutics is currently under evaluation in revenue category among its peers.
Canntab Fundamentals
| Return On Equity | -6.02 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (26.95) % | |||
| Current Valuation | 1.73 M | |||
| Shares Outstanding | 38.91 M | |||
| Shares Owned By Insiders | 15.08 % | |||
| Price To Book | 4.74 X | |||
| Price To Sales | 1.83 X | |||
| Revenue | 293.36 K | |||
| Gross Profit | (939.01 K) | |||
| EBITDA | (2.49 M) | |||
| Net Income | (3.69 M) | |||
| Cash And Equivalents | 691.11 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 126.2 K | |||
| Debt To Equity | 2.43 % | |||
| Current Ratio | 0.57 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (2.85 M) | |||
| Earnings Per Share | (0.1) X | |||
| Beta | 0.9 | |||
| Market Capitalization | 774.29 K | |||
| Total Asset | 2.85 M | |||
| Z Score | 3.6 | |||
| Net Asset | 2.85 M |
About Canntab Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Canntab Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Canntab Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Canntab Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Canntab Pink Sheet
Canntab Therapeutics financial ratios help investors to determine whether Canntab Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canntab with respect to the benefits of owning Canntab Therapeutics security.